Survodutide BI 456906
Survodutide (BI 456906) is Boehringer Ingelheim's investigational dual agonist of the glucagon and GLP-1 receptors: a 29-residue peptide built on a modified glucagon sequence. This survodutide peptide comes as a 10 mg lyophilised vial with an ILS Laboratories lot certificate.
- Order within 15h 47m · ships TueCutoff 3:00 PM ET (12:00 PM PT)
- Arrives Thu, Oct 29 – Tue, Nov 3Free standard shipping on orders over $100
- Free shipment protectionLost, stolen, or damaged? We replace it, on us.
- Overnight and 2-day optionsPick your speed at checkout
- We acceptSecure 256-bit checkout
Verified test results
Every batch, independently verified.
Each batch is analyzed by an ISO/IEC 17025 accredited third-party laboratory before it ships. This is the released report for the size selected above, exactly as the lab signed it.
Certificate of analysis
99.90%
Purity by HPLC
- Lot
- ACE-6990852
- Tested
- Sep 3, 2026
- Labeled
- 10mg
- Measured
- 10.44mg
Full QC panel
5 passed · 2 reportedPurity
HPLC
Net Peptide Content
Identity
HPLC
Fentanyl Screen
Heavy Metals
ICP-MS
Sterility
PCR
Endotoxin
USP <85>
What is survodutide?
Boehringer Ingelheim licensed survodutide from Zealand Pharma and is solely responsible for its development. It starts from the glucagon sequence and is tuned to activate two receptors: the glucagon receptor (GCGR) and the GLP-1 receptor (GLP1R). That pairing is the same one the gut hormone oxyntomodulin hits, which is why it is classed as an oxyntomodulin analogue. In human plasma, the discovery paper put its potency ratio at about 1:8 in favour of the GLP-1 receptor.
Three changes make it last. Position 2 carries 1-aminocyclobutane-1-carboxylic acid (Ac4c), a non-coded amino acid that resists DPP-4; the C-terminus is amidated; and lysine 24 carries a C18 fatty diacid on a glycine-serine linker, which binds albumin and supports once-weekly dosing. It belongs to the same wave of multi-receptor incretin peptides as tirzepatide (GIP + GLP-1) and retatrutide (GIP + GLP-1 + glucagon).
Survodutide identity
| Names | Survodutide, BI 456906, BI-456906 |
|---|---|
| Sequence | H-Ac4c-QGTFTSDYSKYLDERAAKDFI-K*-WLESA-NH2 |
| Modifications | Ac4c (1-aminocyclobutane-1-carboxylic acid) at position 2; Lys24 acylated with a C18 fatty diacid via γGlu and a Gly-Gly-Ser-Gly-Ser-Gly linker; C-terminal amide |
| Length | 29 residues |
| Molecular formula | C192H289N47O61 |
| Molecular weight | 4231.63 g/mol |
| CAS number | 2805997-46-8 |
| PubChem CID | 171378821 |
| Receptor targets | GCGR and GLP1R (dual agonist) |
| This product | 10 mg, lyophilised powder |
Sources: WHO proposed INN list 128, the FDA substance registry (GSRS UNII 2ALA66NS64), KEGG DRUG D12898 and PubChem.
Certificate for the current lot
The current survodutide lot was analysed by ILS Laboratories in San Diego, which states ISO/IEC 17025 accreditation for activities within its published scope. The certificate reports HPLC purity, net peptide content and identity:
| Size | Lot | Laboratory | Analysed | HPLC purity | Measured content | Identity |
|---|---|---|---|---|---|---|
| 10mg | ILS Laboratories | 3 Sep 2026 | 99.90% | 10.44mg | Survodutide |
Transcribed from the certificate issued for each size on sale today. Open the signed certificate for any size under Verified test results above. Every Survodutide COA, lot by lot
Survodutide price
Price per vial and per milligram, read live from the store:
| Size | List price | Price today | Per mg | Availability |
|---|---|---|---|---|
| 10mg | $127.40 | $12.74 | In stock |
Read from the store when this page loads, the same prices the Survodutide product page shows.
Published research on survodutide
- Discovery and preclinical pharmacology (2022). The design from a modified glucagon sequence, the Ac4c and lipidation choices, cAMP potency at both receptors in cell lines and in plasma, and studies in mice. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Zimmermann T, et al. Molecular Metabolism, 2022.
- Choosing the candidate (2024). How survodutide was picked from 19 dual agonists, using markers of GLP-1-receptor engagement (glucose tolerance) and glucagon-receptor engagement (hepatic NNMT mRNA, plasma FGF21). Thomas L, et al. Diabetes, Obesity and Metabolism, 2024.
- Where it acts in the brain (2026). In human and mouse tissue, GLP1R but barely any GCGR was found in the circumventricular organs; labelled survodutide reached those regions without uniformly crossing the blood-brain barrier. Zimmermann T, et al. Molecular Metabolism, 2026.
- Phase 1 (2023). Single and multiple rising-dose studies in healthy men and in Japanese men with overweight; lower plasma amino acids and glucagon were read as engagement of both receptors. Jungnik A, et al., 2023; Yazawa R, et al., 2023.
- Phase 2 in MASH (2024). A placebo-controlled trial in adults with biopsy-confirmed MASH and fibrosis, with histological improvement without worsening fibrosis as the primary end point, which all three dose groups met. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. Sanyal AJ, et al. NEJM, 2024.
- Phase 3 SYNCHRONIZE-1 and -2 (2026). 76-week placebo-controlled trials in adults with obesity, without and with type 2 diabetes; both dose groups met both body-weight primary end points, and gastrointestinal events were the most common adverse events. Survodutide Once Weekly for the Treatment of Adults with Obesity. le Roux CW, et al. NEJM, 2026; Wharton S, et al. NEJM, 2026.
- Phase 3 SYNCHRONIZE-MASLD (2026). A 48-week trial in adults with obesity and steatotic liver disease, with liver fat by MRI-PDFF and body weight as co-primary end points. Kaplan LM, et al. Nature Medicine, 2026.
The phase 3 LIVERAGE trials in MASH with fibrosis and cirrhosis (NCT06632444, NCT06632457) were recruiting in October 2026. A human elimination half-life has not been published in a primary source we could verify.
Regulatory status
Survodutide is investigational. No regulator had approved it by October 2026. FDA gave it Breakthrough Therapy designation in October 2024 for adults with non-cirrhotic MASH and moderate or advanced fibrosis, and the MASH programme also holds FDA Fast Track and EMA PRIME designations. Clean Peptide’s survodutide is a laboratory reference material, not Boehringer Ingelheim’s product, and is not for human or veterinary use.
Related research
- GLP-2 Tirz (tirzepatide) and GLP-3 Reta (retatrutide), with their own certificates.
- Retatrutide price, with survodutide and tirzepatide prices for comparison.
- GLP-1 vs GLP-2 vs GLP-3: what the names mean.
- All incretin analogues.
What is on file, and how it is handled
Every figure below is transcribed from the paperwork for this compound.
Material
- Compound
- Survodutide
- Class
- Dual glucagon / GLP-1 receptor agonist (acylated peptide)
- Form
- Lyophilised powder
- Sizes
- 10mg
- Sequence
- H-Ac4c-QGTFTSDYSKYLDERAAKDFI-K(C18 diacid-γGlu-GGSGSG)-WLESA-NH2
- Formula
- C192H289N47O61
- CAS
- 2805997-46-8
- Mol. weight
- 4231.63 g/mol
- Residues
- 29
Verification
- Identity
- Confirmed on the certificate of analysis
- Purity
- ≥ 99.9% by HPLCSee certificate
- Batch
- ACE-6990852See certificate
- Documentation
- Per-batch certificate of analysis
Handling
- Storage
- Store at −20 °C, protected from light
- Intended use
- In-vitro laboratory research only
QuestionsSurvodutide: frequently asked
What is survodutide?+
Survodutide (BI 456906) is a 29-residue lipidated peptide developed by Boehringer Ingelheim under licence from Zealand Pharma, that activates two receptors: the glucagon receptor and the GLP-1 receptor. It is built on a modified glucagon sequence.
How is survodutide different from tirzepatide?+
Survodutide pairs the glucagon receptor with the GLP-1 receptor; tirzepatide pairs the GIP receptor with the GLP-1 receptor. Survodutide is built on glucagon, tirzepatide on GIP. Tirzepatide is FDA-approved; survodutide is investigational.
What is the survodutide molecular weight?+
4231.63 g/mol for C192H289N47O61 (KEGG DRUG D12898). The CAS number is 2805997-46-8 and the PubChem CID is 171378821.
Is survodutide FDA-approved?+
No. It is in phase 3 trials and had not been approved by any regulator by October 2026. FDA granted it Breakthrough Therapy designation for MASH with moderate or advanced fibrosis in October 2024.
What phase 3 trials has survodutide completed?+
The SYNCHRONIZE programme: SYNCHRONIZE-1 and -2 in obesity without and with type 2 diabetes, SYNCHRONIZE-MASLD in steatotic liver disease, plus Japanese, Chinese and cardiovascular-outcomes trials. The LIVERAGE trials in MASH were still recruiting.
What does the survodutide certificate show?+
The current lot’s ILS Laboratories certificate, listed on this page, gives the lot number, test date, HPLC purity, net peptide content and identity.
Related products
-
Research use only−30%
NeuropeptidesSelank Spray
Original price was: $119.99.$83.99Current price is: $83.99.Learn more about Selank Spray -
Research use only−30%
Incretin AnalogsGLP-3 Reta
Original price was: $97.64.$68.35Current price is: $68.35.Learn more about GLP-3 Reta -
Research use only−30%
Growth Hormone & IGF PeptidesTESAMORELIN
Original price was: $120.00.$84.00Current price is: $84.00.Learn more about TESAMORELIN -
Research use only−30%
Incretin AnalogsGLP-2 Tirz
Original price was: $72.99.$51.09Current price is: $51.09.Learn more about GLP-2 Tirz
